William Blair Predicts Lower Earnings for TransMedics Group

TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) - William Blair lowered their FY2024 earnings estimates for TransMedics Group in a report issued on Tuesday, October 29th. William Blair analyst R. Daniels now forecasts that the company will post earnings of $1.06 per share for the year, down from their previous estimate of $1.33. The consensus estimate for TransMedics Group's current full-year earnings is $1.22 per share. William Blair also issued estimates for TransMedics Group's Q4 2024 earnings at $0.22 EPS, Q3 2025 earnings at $0.45 EPS, Q4 2025 earnings at $0.50 EPS and FY2025 earnings at $1.74 EPS.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last issued its quarterly earnings data on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing analysts' consensus estimates of $0.29 by ($0.17). TransMedics Group had a return on equity of 15.98% and a net margin of 0.84%. The business had revenue of $108.76 million during the quarter, compared to analysts' expectations of $115.00 million. During the same period in the previous year, the business earned ($0.12) earnings per share. The business's quarterly revenue was up 63.7% on a year-over-year basis.

Other research analysts have also recently issued reports about the stock. Oppenheimer dropped their target price on shares of TransMedics Group from $200.00 to $125.00 and set an "outperform" rating on the stock in a report on Tuesday. Robert W. Baird cut their price target on TransMedics Group from $200.00 to $150.00 and set an "outperform" rating on the stock in a report on Tuesday. Canaccord Genuity Group decreased their price objective on shares of TransMedics Group from $169.00 to $109.00 and set a "buy" rating for the company in a research report on Tuesday. Morgan Stanley increased their price target on TransMedics Group from $104.00 to $145.00 and gave the stock an "equal weight" rating in a research report on Monday, July 15th. Finally, Baird R W upgraded TransMedics Group to a "strong-buy" rating in a research note on Tuesday, September 24th. One research analyst has rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, TransMedics Group has an average rating of "Buy" and a consensus price target of $144.80.

TransMedics Group Trading Up 0.2 %

NASDAQ:TMDX traded up $0.15 during midday trading on Thursday, hitting $82.07. The stock had a trading volume of 1,166,719 shares, compared to its average volume of 932,566. The stock has a 50-day moving average of $144.20 and a 200 day moving average of $139.76. The company has a market capitalization of $2.74 billion, a price-to-earnings ratio of 86.14 and a beta of 1.99. TransMedics Group has a one year low of $36.42 and a one year high of $177.37. The company has a quick ratio of 8.48, a current ratio of 9.37 and a debt-to-equity ratio of 2.67.

Hedge Funds Weigh In On TransMedics Group

Institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its position in TransMedics Group by 2.8% during the 4th quarter. Vanguard Group Inc. now owns 1,865,115 shares of the company's stock worth $147,214,000 after purchasing an additional 50,673 shares during the period. Allspring Global Investments Holdings LLC boosted its holdings in TransMedics Group by 3.1% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 730,010 shares of the company's stock worth $53,977,000 after acquiring an additional 21,737 shares during the period. Oak Ridge Investments LLC grew its position in TransMedics Group by 59.5% in the first quarter. Oak Ridge Investments LLC now owns 18,267 shares of the company's stock valued at $1,351,000 after acquiring an additional 6,813 shares in the last quarter. BNP Paribas Financial Markets raised its stake in shares of TransMedics Group by 35.1% during the first quarter. BNP Paribas Financial Markets now owns 17,390 shares of the company's stock valued at $1,286,000 after purchasing an additional 4,518 shares during the period. Finally, Fidelis Capital Partners LLC purchased a new position in shares of TransMedics Group in the first quarter valued at $35,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at TransMedics Group

In other news, CEO Waleed H. Hassanein sold 8,625 shares of TransMedics Group stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $153.42, for a total transaction of $1,323,247.50. Following the sale, the chief executive officer now owns 61,643 shares in the company, valued at approximately $9,457,269.06. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other TransMedics Group news, insider Tamer I. Khayal sold 2,958 shares of the stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $148.24, for a total transaction of $438,493.92. Following the sale, the insider now owns 20,843 shares in the company, valued at approximately $3,089,766.32. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Waleed H. Hassanein sold 8,625 shares of the company's stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $153.42, for a total transaction of $1,323,247.50. Following the completion of the transaction, the chief executive officer now owns 61,643 shares in the company, valued at approximately $9,457,269.06. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 61,247 shares of company stock valued at $9,518,181 in the last quarter. Corporate insiders own 7.00% of the company's stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.